versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern
Search Results
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Featured Updates to the NCCN Guidelines
Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S. Berek, Lee-may Chen, Mihaela Cristea, Marie DeRosa, Adam C. ElNaggar, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Angela Jain, Carolyn Johnston, Charles A. Leath III, Joyce Liu, Haider Mahdi, Daniela Matei, Michael McHale, Karen McLean, David M. O’Malley, Richard T. Penson, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Paul Sabbatini, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh
Antoni Ribas
activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients . Proc Natl Acad Sci U S A 2003 ; 100 : 4712 – 4717 . 63. Phan GQ Yang JC Sherry RM . Cancer
David M. O’Malley
, . Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial . Lancet 2017 ; 390 : 1949 – 1961 . 10.1016/S0140-6736(17)32440-6 28916367
Jeffrey Crawford, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, David C. Dale, George D. Demetri, Harry P. Erba, James Foran, Alison G. Freifeld, Marti Goemann, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Laura Boehnke Michaud, Sarah C. Miyata, Martin S. Tallman, Saroj Vadhan-Raj, Peter Westervelt, and Michael K. Wong
; 11 : 172 – 179 . 28 Numnum TM Kimball KJ Rocconi RP . Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma—a cost-effectiveness analysis . Int J Gynecol Cancer 2007 ; 17 : 1019 – 1024
recommendations,” said Dr. Morgan. The NCCN Guidelines continue to recommend that women with borderline epithelial ovarian cancer of low malignant potential be primarily surgically managed. In contrast to patients with frankly invasive ovarian carcinoma, women
Matthieu Picard, Ursula A. Matulonis, and Mariana Castells
. 13. Morgan JS Adams M Mason MD . Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma . Eur J Cancer 1994 ; 30A : 1205 – 1206 . 14. Navo M Kunthur A Badell ML . Evaluation of the incidence of
Mary B. Daly, Tuya Pal, Michael P. Berry, Saundra S. Buys, Patricia Dickson, Susan M. Domchek, Ahmed Elkhanany, Susan Friedman, Michael Goggins, Mollie L. Hutton, CGC, Beth Y. Karlan, Seema Khan, Catherine Klein, Wendy Kohlmann, CGC, Allison W. Kurian, Christine Laronga, Jennifer K. Litton, Julie S. Mak, LCGC, Carolyn S. Menendez, Sofia D. Merajver, Barbara S. Norquist, Kenneth Offit, Holly J. Pederson, Gwen Reiser, CGC, Leigha Senter-Jamieson, CGC, Kristen Mahoney Shannon, Rebecca Shatsky, Kala Visvanathan, Jeffrey N. Weitzel, Myra J. Wick, Kari B. Wisinski, Matthew B. Yurgelun, Susan D. Darlow, and Mary A. Dwyer
former population. 55 , 57 , 69 – 72 Mutations are also associated with nonmucinous ovarian carcinoma as opposed to mucinous. 56 , 58 Mucinous epithelial ovarian carcinomas may be associated with other gene mutations, such as TP53 mutations, 73 which
Saranya Chumsri, Jodi Weidler, Siraj Ali, Sohail Balasubramanian, Gerald Wallweber, Lisa DeFazio-Eli, Ahmed Chenna, Weidong Huang, Angela DeRidder, Lindsay Goicocheal, and Edith A. Perez
extracellular domain mutations of ERBB2 . Proc Natl Acad Sci U S A 2012 ; 109 : 14476 – 14481 . 27. Cancer Genome Atlas Research Network . Integrated genomic analyses of ovarian carcinoma . Nature 2011 ; 474 : 609 – 615 . 28
Michael J. Hall, Andrea D. Forman, Robert Pilarski, Georgia Wiesner, and Veda N. Giri
-ICC) Annual Meeting ; October 7-8, 2013 ; Anaheim, California . 11. Norquist BM Pennington KP Agnew KJ . Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing . Gynecol Oncol 2013
Michelle C. Nguyen, Manisha H. Shah, David A. Liebner, Floor J. Backes, John Phay, and Lawrence A. Shirley
. Central nervous system metastases in patients with ovarian carcinoma. A report of 23 cases and a literature review . Ann Oncol 1995 ; 6 : 571 – 574 . 23. Palmieri D Chambers AF Felding-Habermann B . The biology of metastasis to a sanctuary